We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Polyglutamine (polyQ) repeat diseases
- Repeat expansion diseases (1)
- Repeat expansion diseases (2)
- Suppressing dominant disease genes
- How to accomplish reduction in expression?
- Reduction in expression by RNA interference
- A cartoon of the RNAi pathway
- Human spinocerebellar ataxia type 1 (SCA1)
- Effects of shSCA1 on mutant human ataxin-1 (1)
- Effects of shSCA1 on mutant human ataxin-1 (2)
- Testing shAtaxin1 in vivo: dendritic atrophy
- Testing shAtaxin1 in vivo: hSCA1 transgenics
- Testing shAtaxin1 in vivo: ataxia
- How to accomplish RNAi in target brain cells
- AAVs - deliver genetic material to the brain (1)
- AAVs - deliver genetic material to the brain (2)
- Testing shAtaxin1 in vivo: delivery issues
- shSCA1 and shLacZ transcripts in cerebellum
- shSCA1: impact on behavior
- Advantage of half-transduced lobules
- Photomicrographs from half-transduced lobules
- shSCA1 normalizes molecular layer widths
- shSCA1 reduces ataxin-1 aggregates
- Summary (1)
- Huntington's disease: a brief history
- Huntington's disease (HD)
- Mutant huntingtin expression downstream effects
- Designing shRNAs for huntingtin
- shHD2.1 reduces HD-N171-82Q mRNA
- shHD2.1 reduces HD-N171-82Q Protein
- Testing shHD in vivo
- shRNA delivery to mouse brain using AAV1
- shHD2.1 reduces transgene expression in vivo
- shHD2.1 reduces Htt-immunoreactive inclusions
- shHD2.1 improves rotarod performance in mice
- Gait abnormalities in HD mice
- shHD2.1 improves stride length in mice
- Summary (2)
- Acknowledgements
Topics Covered
- Brain diseases and molecular therapies
- RNA interference
- Mice models of brain disease
- Viral vectors
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Davidson, B.L. (2007, October 1). RNA interference for neurodegenerative diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/FEAS8148.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Beverly L. Davidson has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.